Inventiva Reports First Quarter 2025 Financials: Cash Position Declines

In the first quarter of 2025, Inventiva, a clinical-stage biopharmaceutical company, reported its financial results. As of March 31, the company held €67.9 million in cash and equivalents, down from €96.6 million at the end of 2024. This decline is attributed mainly to expenses related to the lanifibranor development program.

Inventiva anticipates that its current financial resources will sustain operations until Q3 2026, accounting for recent financing activities and expected milestones. However, additional funding will be pursued to support long-term goals for lanifibranor’s development and commercialization through potential strategic partnerships or transactions.

The company recognized no revenue in Q1 2025, consistent with the same period in 2024. Significant R&D progress included French authorization for a pipeline prioritization plan and the completion of patient enrollment for the NATiV3 Phase 3 trial.